Publications by authors named "D Mathai"
Article Synopsis
- Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA shows potential for treating depression and PTSD, with possible approval as medicines within the next decade.
- A study involving 879 U.S. healthcare professionals found most respondents had strong belief in the therapeutic benefits of these substances, but exhibited low knowledge about their risks and uses.
- Factors such as prior psychedelic use, greater self-rated knowledge, younger age, and specific professional roles influenced openness to using these therapies, highlighting the need for more training and education on the topic.
Article Synopsis
- The study aimed to create a predictive model for whether infants born preterm or with low birth weight were fed their mother's own milk (MOM) at discharge, focusing on social determinants of health (SDOH) and maternal-neonatal factors.
- It analyzed data from 986 neonates at an inner-city hospital, revealing that feeding MOM was less common among non-Hispanic Black mothers compared to Hispanic mothers, a trend that remained consistent before and after a donor human milk program was introduced.
- The model showed that lower odds of feeding MOM at discharge were linked to factors like higher neighborhood poverty, maternal substance use, and younger maternal age, but these odds did not improve after the implementation of the donor human milk program.
Background: Improving safe and effective access to ketamine therapy is of high priority given the growing burden of mental illness. Telehealth-supported administration of sublingual ketamine is being explored toward this goal.
Methods: In this longitudinal study, moderately-to-severely depressed patients received four doses of ketamine at home over four weeks within a supportive digital health context.
Rationale: N-methyl-D-aspartate receptor-mediated dissociatives and serotonergic hallucinogens are being increasingly used in therapeutic interventions that involve nonordinary states of consciousness and may represent a unique mental health paradigm wherein pharmacologically induced experiences are conducive to psychological well-being.
Objective: The aim of this study was to further understand how the phenomenological and health-promoting effects of high-dose dextromethorphan (DXM) compared to psilocybin in the same participants when administered under experimental conditions that are typical of therapeutic psychedelic trials.
Methods: Single, acute oral doses of DXM (400 mg/70 kg), psilocybin (10, 20, 30 mg/70 kg), and inactive placebo were administered under double-blind and psychologically supportive conditions to 20 healthy participants with histories of hallucinogen use.
Introduction: The classic psychedelic psilocybin, found in some mushroom species, has received renewed interest in clinical research, showing potential mental health benefits in preliminary trials. Naturalistic use of psilocybin outside of research settings has increased in recent years, though data on the public health impact of such use remain limited.
Methods: This prospective, longitudinal study comprised six sequential automated web-based surveys that collected data from adults planning to take psilocybin outside clinical research: at time of consent, 2 weeks before, the day before, 1-3 days after, 2-4 weeks after, and 2-3 months after psilocybin use.